stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Return on assets
Royalty Pharma PLC's return on assets over the twelve months to 30 September 2026 was 0.00%, down 4.1 percentage points from fiscal 2025 (4.07%). Over the past ten years it has ranged from 0.00% (fiscal 2018) to 37.7% (fiscal 2019); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 4.07% | (0.89) |
| FY2024 | 4.96% | (1.88) |
| FY2023 | 6.84% | 6.59 |
| FY2022 | 0.25% | (3.45) |
| FY2021 | 3.70% | (3.15) |
| FY2020 | 6.85% | (30.88) |
| FY2019 | 37.7% | 37.73 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.5% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| ARGX argenex SE compare | 0.00% |
| RPRX Royalty Pharma PLC | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement